You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Ovarian Cancer Consult: Adapting to PARP Inhibitors

  • Authors: Bradley J. Monk, MD, FACS, FACOG; Shannon N. Westin, MD, MPH; Floor Backes, MD
  • CME / ABIM MOC Released: 1/20/2023
  • Valid for credit through: 1/20/2024
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for oncologists, obstetrician/gynecologists, surgeons, and pathologists. 

The goal of this activity is to improve knowledge and skills of the ovarian cancer (OC) multidisciplinary team with regard to the management of patients with OC receiving PARP inhibitors.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical trial data associated with PARP inhibitor therapy for patients with OC
  • Have greater competence related to
    • Mitigating treatment‐related adverse events for patients with OC receiving PARP inhibitors
    • Tailoring treatment decisions for patients with OC


Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


  • Bradley J. Monk, MD, FACS, FACOG

    Division of Gynecologic Oncology
    University of Arizona College of Medicine
    Director, Principal Investigator, Community Research Development
    HonorHealth Research Institute
    Phoenix, Arizona


    Bradley J. Monk, MD, FACS, FACOG, has the following relevant financial relationships:
    Consultant or advisor for: Acrivon Therapeutics; Adaptimmune Therapeutics; Agenus; Akeso Bio; Amgen; Aravive; AstraZeneca; Bayer; Clovis Oncology; Eisai; Elevar Therapeutics; EMD Merck; Genmab/Seagen; Gradalis; Hengrui; ImmunoGen; Iovance Biotherapeutics; Karyopharm; Laekna Therapeutics; MacroGenics; Merck; Mersana Therapeutics; Myriad Genetics; Novocure; OncoC4; Panavance Therapeutics; Pfizer; Pieris Pharmaceuticals; Puma Biotechnology; Regeneron; Roche/Genentech; Sorrento Therapeutics; TESARO/GlaxoSmithKline; US Oncology Research; VBL Therapeutics; Verastem Oncology; Zentalis Pharmaceuticals
    Speaker or member of speakers bureau for: AstraZeneca; Clovis Oncology; Eisai; Merck; Myriad Genetics; Roche/Genentech; TESARO/GlaxoSmithKline
    Other: Investigator: Gradalis Inc.; US Oncology Research; Honorarium: Novartis

  • Floor Backes, MD

    Professor, Gynecologic Oncology
    The Ohio State University
    and James Cancer Hospital
    Columbus, Ohio


    Floor Backes, MD, has the following relevant financial relationships:
    Consultant or advisor for: Agenus; AstraZeneca; Eisai; Genentech; GlaxoSmithKline; Merck
    Research funding from: Clovis Oncology; Eisai; ImmunoGen; Merck

  • Shannon N. Westin, MD, MPH

    Medical Director, Gynecologic Oncology Center
    Director, Early Drug Development and Phase 1
    Department of Gynecologic Oncology and Reproductive Medicine
    University of Texas
    MD Anderson Cancer Center
    Houston, Texas


    Shannon N. Westin, MD, MPH, has no relevant financial relationships.


  • Amy Furedy, RN, OCN

    Medical Education Director, Medscape, LLC


    Amy Furedy, RN, OCN, has no relevant financial relationships.

Compliance Reviewer

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

Developed through a collaboration between the GOG Foundation, Inc. and Medscape Oncology

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Ovarian Cancer Consult: Adapting to PARP Inhibitors

Authors: Bradley J. Monk, MD, FACS, FACOG; Shannon N. Westin, MD, MPH; Floor Backes, MDFaculty and Disclosures

CME / ABIM MOC Released: 1/20/2023

Valid for credit through: 1/20/2024


Contents of This CME Activity

All sections of this activity are required for credit.

Adapting to PARP Inhibitors: Frontline Treatment of Advanced Ovarian Cancer

How would you treat a woman with newly diagnosed advanced ovarian cancer?
Bradley J. Monk, MD, FACS, FACOG

Treatment of Platinum-Sensitive Ovarian Cancer

How would you treat a patient with platinum-sensitive ovarian cancer following cytoreductive surgery?
Shannon N. Westin, MD, MPH

Adapting PARP Inhibitors to Treatment of Recurrent Ovarian Cancer

Are you up to date on PARP inhibitor maintenance in platinum-sensitive recurrent ovarian cancer?
Floor Backes, MD

Learning Feedback Questions

Please answer these questions to complement your learning experience.

  • Print